Claims for Patent: 8,865,718

Summary for Patent: 8,865,718

Title:	Heterocyclic inhibitors of glutaminase
Abstract:	The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
Inventor(s):	Li; Jim (San Francisco, CA), Chen; Lijing (Cupertino, CA), Goyal; Bindu (Fremont, CA), Laidig; Guy (Woodside, CA), Stanton; Timothy Friend (Daly City, CA), Sjogren; Eric Brian (Mountain View, CA)
Assignee:	Calithera Biosciences Inc. (South San Francisco, CA)
Application Number:	14/051,216
Patent Claims:	1. A method of treating cancer, comprising administering a compound of formula I, ##STR00926## or a pharmaceutically acceptable salt thereof, wherein: L represents CH.sub.2SCH.sub.2, CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, CH.sub.2, CH.sub.2S, SCH.sub.2, CH.sub.2NHCH.sub.2, CH.dbd.CH, or ##STR00927## wherein any hydrogen atom of a CH or CH.sub.2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH.sub.2 unit of CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2 or CH.sub.2 may be replaced by hydroxy; one X represents S and the other X represents CH.dbd.CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or CH.sub.2O(CO)R.sub.7; R.sub.7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R.sub.3(CO); R.sub.1 and R.sub.2 each independently represent H, alkyl, alkoxy or hydroxy; R.sub.3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R.sub.8)(R.sub.9)(R.sub.10), N(R.sub.4)(R.sub.5) or OR.sub.6, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.4 and R.sub.5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; and R.sub.8, R.sub.9 and R.sub.10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R.sub.8 and R.sub.9 together with the carbon to which they are attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7, and wherein at least two of R.sub.8, R.sub.9 and R.sub.10 are not H. 2. The method of claim 1, wherein L represents CH.sub.2SCH.sub.2, CH.sub.2CH.sub.2, CH.sub.2S or SCH.sub.2. 3. The method of claim 1, wherein L represents CH.sub.2CH.sub.2. 4. The method of claim 1, wherein Y represents H. 5. The method of claim 1, wherein Z represents R.sub.3(CO). 6. The method of claim 5, wherein each occurrence of R.sub.3 is not identical. 7. The method of claim 1, wherein R.sub.1 and R.sub.2 each represent H. 8. The method of claim 1, wherein R.sub.3, independently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. 9. The method of claim 1, wherein R.sub.3, independently for each occurrence, represents C(R.sub.8)(R.sub.9)(R.sub.10), wherein R.sub.8 represents substituted or unsubstituted aryl, arylalkyl, heteroaryl or heteroaralkyl, R.sub.9 represents H, and R.sub.10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl. 10. The method of claim 9, wherein R.sub.8 represents substituted or unsubstituted aryl, arylalkyl, or heteroaryl. 11. The method of claim 9 or 10, wherein R.sub.10 represents hydroxy, hydroxyalkyl, or alkoxy. 12. The method of claim 1, wherein L represents CH.sub.2CH.sub.2, Y represents H, Z represents R.sub.3(CO), R.sub.1 and R.sub.2 each represent H, and R.sub.3, independently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. 13. The method of claim 12, wherein each occurrence of R.sub.3 is identical. 14. The method of claim 1, wherein the cancer is selected from acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), Burkitt's lymphoma, glioma, melanomas, breast cancer, pancreatic cancer, non-small cell lung cancer, colon cancer or kidney cancer. 15. The method of claim 1, wherein the method comprises conjointly administering one or more chemotherapeutic agents. 16. The method of claim 15, wherein the one or more chemotherapeutic agents is selected from aminoglutethimide, amsacrine, anastrozole, asparaginase, Bacillus Calmette-Guerin vaccine (bcg), bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, or vinorelbine. 17. The method of claim 15, wherein the method comprises conjointly administering chemotherapeutic agents in a combination selected from: Doxorubicin, Bleomycin, and Vinblastine; Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine; Doxorubicin and Cyclophosphamide; Doxorubicin and Cisplatin; Cyclophosphamide and Doxorubicin; Cyclophosphamide, Doxorubicin, and Etoposide; Cyclophosphamide and Doxorubicin; Doxorubicin and Dacarbazine; Doxorubicin and Cisplatin; Cytarabine and Daunorubicin; Bleomycin, Lomustine, Doxorubicin, and Vinblastine; Carmustine, Cyclophosphamide, Vinblastine, Procarbazine, and Prednisone; Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Filgrastim; Bleomycin, Etoposide, and Cisplatin; Bleomycin, Cisplatin, Ifosfamide, and Mesna; Bleomycin, Vincristine, Cisplatin, and Mitomycin; Cytarabine and Asparaginase; Cisplatin, Methotrexate, Bleomycin, and Vincristine; Cyclophosphamide, Doxorubicin, and Fluorouracil; Cyclophosphamide, Daunorubicin, Vincristine, Prednisone, and Asparaginase; Cyclophosphamide, Doxorubicin, Methotrexate, and Procarbazine; Cyclophosphamide, Doxorubicin, and Cisplatin; Carboplatin and Paclitaxel; Cyclophosphamide, Doxorubicin, and Vincristine; Cyclophosphamide, Doxorubicin, Vincristine, and Etoposide; Cyclophosphamide, Doxorubicin, and Etoposide; Cyclophosphamide and Carboplatin; Cisplatin and Etoposide; Cyclophosphamide, Epirubicin, and Fluorouracil; Cyclophosphamide, Etoposide, and Prednisone; Cyclophosphamide, Etoposide, Prednisone, and Bleomycin; Cyclophosphamide, Etoposide, and Vincristine; Cisplatin and Fluorouracil; Carboplatin and Fluorouracil; Cyclophosphamide or Cyclophosphamide, Altretamine, Doxorubicin, and Cisplatin; Chlorambucil, Vinblastine, Procarbazine, and Prednisone; Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone; Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Bleomycin; Cyclophosphamide, Doxorubicin, and Cisplatin; Bleomycin, Cisplatin, Vincristine, and Mitomycin; Methotrexate, Fluorouracil, and Cyclophosphamide; Cyclophosphamide, Methotrexate, Fluorouracil, and Prednisone; Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, and Prednisone; Cisplatin, Methotrexate, and Vinblastine; Cyclophosphamide, Mitoxantrone, and Fluorouracil; Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisone; Cisplatin, Vincristine, and Bleomycin; Cisplatin, Vincristine, Doxorubicin, and Etoposide; Cyclophosphamide, Vincristine, Methotrexate, Leucovorin, and Cytarabine; Cyclophosphamide, Vincristine, Methotrexate, and Prednisone; Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, and Prednison; Cyclophosphamide, Vincristine, and Prednisone; Cyclophosphamide, Vincristine, Cisplatin, and Etoposide; Cyclophosphamide, Vincristine, Procarbazine, and Prednisone; Chlorambucil and Prednisone; Cyclophosphamide and Cisplatin; Cisplatin and Paclitaxel; Cisplatin, Vinblastine, and Dacarbazine; Carboplatin, Etoposide, Ifosfamide, and Mesna; Cyclophosphamide, Vincristine, and Prednisome; Lomustine, Procarbazine, and Prednisone; Cyclophosphamide, Vincristine, Doxorubicin, and Dacarbazine; Daunorubicin and Cytarabine; Daunorubicin, Cytarabine, and Thioguanine; Daunorubicin, Cytarabine, and Etoposide; Daunorubicin, Cytarabine, and Thioguanine; Cisplatin, Cytarabine, and Dexamethasone; Doxorubicin and Ifosfamide; Dacarbazine and Tamoxifen; Daunorubicin, Vincristine, and Prednisone; Etoposide, Doxorubicin, and Cisplatin; Etoposide and Carboplatin; Etoposie, Fluorouracil, and Cisplatin; Etoposide, Leucovorin, and Fluorouracil; Mitoxantrone, Etoposide, and Cytarabine; Etoposide and Cisplatin; Etoposide and Vinblastine; Fluorouracil, Doxorubicin, and Cyclophosphamide; Fluorouracil, Doxorubicin, and Mitomycin; Methotrexate, Leucovorin, and Doxorubicin; Fluorouracil, Doxorubicin, and Cisplatin; Fluorouracil and Leucovorin; Fluorouracil, Cyclophosphamide, and Epirubicin; Fluorouracil, Etoposide, and Cisplatin; Flutamide and Leuprolide; Flutamide and Goserelin acetate implant; Methotrexate and Leucovorin; Altretamine, Cyclophosphamide, Methotrexate, and Fluorouracil; Ifosfamide, Carboplatin, Etoposide, Paclitaxel, and Mesna; Methotrexate, Mercaptopurine, and Leucovorin; Ifosfamide, Etoposie, and Mesna; Ifosfamide, Etoposide, and Mesna; Ifosfamide, Cisplatin, and Doxorubicin; Vincristine, Carmustine, Cyclophosphamide, Prednisone, and Melphalan; Methotrexate, Leucovorin, Dactinomycin, and Cyclophosphamide; Methotrexate, Doxorubicin, Cyclophosphamide, and Lomustine; Methotrexate, Leucovorin, Doxorubicin, Cyclophosphamide, Vincristine, Bleomycin, and Prednisone; Mesna, Doxorubicin, Ifosfamide, and Dacarbazine; Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Dexamethasone, Methotrexate, and Leucovorin; Methotrexate, Bleomycin, and Cisplatin; Mitoxantrone and Cytarabine; Methotrexate, Fluorouracil, and Leucovorin; Ifosfamide, Carboplatin, Etoposide, and Mesna; Mesna, Ifosfamide, Mitoxantrone, and Etoposide; Carmustine, Etoposide, Cytarabine, and Melphalan; Bleomycin, Vincristine, Cisplatin, and Mitomycin; Mechlorethamine, Vincristine, and Procarbazine; Mechlorethamine, Vincristine, Procarbazine, and Prednisone; Mechlorethamine, Vincristine, Procarbazine, Prednisone, Doxorubicin, Bleomycin, and Vinblastine; Melphalan and Prednisone; Mitoxantrone and Prednisone; Methotrexate and Mercaptopurine; Methotrexate, Mercaptopurine, Vincristine, and Prednisone; Methotrexate, Leucovorin, Cisplatin, and Doxorubicin; Mitomycin and Vinblastine; Mitoxantrone and Etoposide; Vinblastine, Doxorubicin, and Cisplatin; Vinblastine and Cisplatin; Mechlorethamine, Vinblastine, Procarbazine, and Prednisone; Mitoxantrone, Fluorouracil, and Leucovorin; Mitoxantrone, Vinblastine, and Vincristine; Vincristine, Prednisone, and Doxorubicin; Vincristine, Prednisone, Doxorubicin, and Procarbazine; Cisplatin and Doxorubicin; Cisplatin, Doxorubicin, and Cyclophosphamide; Cisplatin and Doxorubicin; Paclitaxel, Carboplatin or Paclitaxel, and Cisplatin; Lomustine, Procarbazine, and Vincristine; Paclitaxel and Estramustine; Cisplatin, Fluorouracil, and Leucovorin; Prednisone, Vincristine, and Lomustine; Prednisone, Methotrexate, Leucovorin, Doxorubicin, Cyclophosphamide, and Etoposide; Prednisone, Doxorubicin, Cyclophosphamide, Etoposide, Cytarabine, Bleomycin, Vincristine, Methotrexate, Leucovorin, and Cotrimoxazole; Prednisone, Doxorubicin, Cyclophosphamide, Etoposide, Mechlorethamine, Vincristine, Procarbazine, Methotrexate, and Leucovorin; Cisplatin and Teniposide; Prednisone, Vincristine, and Asparaginase; Cisplatin, Vinblastine, and Bleomycin; Prednisone, Vincristine, Daunorubicin, and Asparaginase; Streptozocin, Mitomycin, and Fluorouracil; Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, and Prednisone; Paclitaxel, Cisplatin, and Fluorouracil; Paclitaxel, Ifosfamide, Mesna, and Cisplatin; Methotrexate, Cytarabine, and Hydrocortisone; Cyclophosphamide, Topotecan, and Mesna; Cyclophosphamide, Dactinomycin, Vinblastine, Cisplatin, and Bleomycin; Vincristine, Dactinomycin, and Cyclophosphamide; Vincristine, Cyclophosphamide, Doxorubicin, Dactinomycin, and Vincristine; Vincristine, Doxorubicin, and Dexamethasone; Vinblastine, Doxorubicin, Thiotepa, and Fluoxymesterone; Vincristine, Carmustine, Doxorubicin, and Prednisone; Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone; Vinorelbine and Cisplatin; Vincristine, Cyclophosphamide, Doxorubicin, and Prednisone; Vinorelbine and Doxorubicin; Vinblastine, Cisplatin, Ifosfamide, and Mesna; Etoposide, Cisplatin, Ifosfamide, and Mesna; Mitomycin and Vinblastine; Vincristine, Melphalan, Cyclophosphamide, and Prednisone; Etoposide and Cisplatin; Etoposide, Thioguanine, Daunorubicin, and Cytarabine; Cytarabine, Daunorubicin, and Mitoxantrone; Cytarabine and Idarubicin; Cytarabine and Daunorubicin; Cytarabine and Mitoxantrone; or Methylprednisolone, Vincristine, Lomustine, Procarbazine, Hydroxyurea, Cisplatin, Cytarabine, and Dacarbazine. 18. The method of claim 1, wherein the method further comprises administering radiation therapy. 19. The method of claim 1, wherein the method further comprises administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof.

Details for Patent 8,865,718

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2031-11-21
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2031-11-21
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2031-11-21